ABSTRACT Background: Cancer has become a leading cause of death world-wide. In Hong Kong, cancer accounted for 24.8% of deaths in 1980, rising to 31.3% in 1998. The conventional treatment of cancer usually includes surgery, radiotherapy and chemotherapy. These conventional therapies do not guarantee not relapse and are often associated with serious side effects. Using Chinese Medicine (CM) as an adjunctive treatment is commonly practiced in Chinese Communities to support patients being treated with conventional modern medicine, with the aim of alleviating the side effects, and improving self-defense and their quality of life. Well-designed and conducted clinical trials could give evidence of the efficacy of CM. This study investigated the clinical efficacy through the well designed clinical trial, and the implementation of carrying out the trial, to assess the adjuvant and supportive effect on lung cancer patients. Methods: The clinical study was designed as a randomized controlled trial to investigate the dose-dependent effects. Primary endpoint was the difference of Functional Assessment of Cancer Therapy-General (FACT-G) score. Results: 41 eligible subjects were enrolled and randomly divided into 2 groups, 21 in high dose group and 20 in low dose group. Sub-domains of PWB (Physical well-being) and EWB (Emotional well-being) as well as FACT-G total score were significantly improved in high dose group when compared with low dose group after 12 weeks treatment (p = 0.015, 0.006 and 0.012, respectively). Conclusions: Holistic approach using quality of life as parameters to evaluate the efficacy of CM is an important compromise. Well-designed clinical trial can provide convincing evidence to support CM’s efficacy. The study demonstrated that quality of life of patients with lung cancer could be beneficial from the supportive care with CM.
Cite this paper
nullK. Cheng and P. Leung, "Use of Chinese Herbal Medicine as an Adjuvant for Cancer Treatment: A Randomized Controlled Dose-Finding Clinical Trial on Lung Cancer Patients," Journal of Cancer Therapy, Vol. 2 No. 2, 2011, pp. 91-98. doi: 10.4236/jct.2011.22010.
 Hong Kong Cancer Registry, “Cancer Incidence and Mortality in Hong Kong 1998-1999,” Hong Kong Authority, Hong Kong, 2000.
X. S. Wang, L. J. Di, C. C. Reyes-Gibby, H. Guo, S. J. Liu and C. S. Cleeland, “End-of-Life Care in Urban Areas of China: A Survey of 60 Oncology Clinicians,” Journal of Pain and Symptom Management, Vol. 27, No. 2, 2004, pp. 125-132. doi:10.1016/j.jpainsymman.2003.06.002
 K. Chen, P. P. Wang, B. C. Sun, et al., “Twenty-Year Secular Changes in Sex Specific Lung Cancer Incidence Rates in an Urban Chinese Population,” Lung Cancer, Vol. 51, No. 1, 2006, pp. 13-19. doi:10.1016/j.lungcan.2005.08.013
L. D. Li, F. Z. Lu, S. W. Zhang, R. Mu, X. D. Sun, X. M. Huangpu, J. Sun, Y. S. Zhou, N. H. Ouyang, K. Q. Rao, Y. D. Chen and A. M. Sun, “Analysis of Cancer Mortality and Distribution in China from Year 1990 through 1992: an Epidemiologic Study,” Chinese Journal of Oncology, Vol. 18, No. 6, 1996, pp. 403-405.
Y. S. Zhou, S. W. Zhang and L. D. Li, “Analysis for Death for All and Malignant Tumors for China Population,” Bull China Can, Vol. 6, 1997, pp. 9-11.
National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health Investigate for Malignant Tumor Mortality in China, People’s Health Publishing House, Beijing, 1979.
L. D. Li, F. Z. Lu, S. W. Zhang, et al., “Analysis of Variation Trend and Short-Term Detection of Chinese Malignant Tumor Mortality during Twenty Years,” Chinese Journal of Oncology, Vol. 19, No. 1, 1997, pp. 3-9.
T. K. Yun and S. Y. Choi, “Non-Organ Specific Cancer Prevention of Ginseng: A Prospective Study in Korea,” International Journal of Epidemiology, Vol. 27, No. 3, 1998, pp. 359-364. doi:10.1093/ije/27.3.359
B. H. Lao, H. C. Ruckle and T. Botolazzo, “Chinese Medicinal Herbs Inhibit Growth of Murine Renal Cell Carcinoma,” Cancer Biother, Vol. 9, No. 2, 1994, pp. 153- 161. doi:10.1089/cbr.1994.9.153
J. Z. Wang, H. Tsumara and K. Shimura, “Antitumor Activity of Polysaccharide from Chinese Medicinal Herb, Acanthopanax Giraldii Harms,” Cancer Letters, Vol. 65, No. 1, 1992, pp. 79-84.doi:10.1016/0304-3835(92)90216-I
T. Tode, Y. Kikuchi and T. Kita, “Inhibitory Effects by Oral Administration of Ginsenoside Rh2 on the Growth of Human Ovarian Cancer Cells in Nude Mice,” Journal of Cancer Research and Clinical Oncology, Vol. 120, No. 1-2, 1993, pp. 24-26. doi:10.1007/BF01200720
J. K. Liu, “Prospect of the Development of New Natural Drugs as Foreshadowed by the R & D of the World 20 Leading Pharmaceutical Corporations,” Chinese Traditional and Herbal Drugs, Vol. 31, No. 7, 2000, pp. 481-487.
L. A. Ries, C. L. Kosary and B. F. Hankey, “Lung and Bronchus Cancer: SEER Cancer Statistics Review, 1973-1996,” National Cancer Institute, Bethesda, MD, 1999.
Z. Rosenberg, “Treating the Undesirable Effects of Radiation and Chemotherapy with Chinese Medicine,” Jour- nal of Chinese Medicine, Vol. 55, No. 55, September 1997, pp. 29-30.
S. Y. Lin, L. M. Liu, L. C. Wu, “Effects of Shenmai Injection on Immune Function in Stomach Cancer Patients after Chemotherapy,” Chinese Journal of Integrated Traditional and Western Medicine, Vol. 15, No. 4, 1995, pp. 451-453.
H. Boon, J. B. Brown, A. Gavin, M. A. Kennard and M. Stewart, “Breast Cancer Survivors’ Perceptions of Complementary/Alternative Medicine (CAM): Making the Decision to Use or Not to Use,” Qualitative Health Research, Vol. 9, No. 5, 1999, pp. 639-653.doi:10.1177/104973299129122135
M. A. Richardson, T. Sanders, J. L. Palmer, A. Greisinger and S. E. Singletary, “Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology,” Journal of Clinical Oncology, Vol. 18, No. 13, 2000, pp. 2505-2514.
W. XU, A. D. TOWERS, P. LI and J.-P. Collet, “Traditional Chinese Medicine in Cancer Care: Perspectives and Experiences of Patients and Professionals in China,” European Journal of Cancer Care, Vol. 15, No. 4, September 2006, pp. 397-403.doi:10.1111/j.1365-2354.2006.00685.x
J. L. Tang, S. Y. Zhan and E. Ernst, “Review of Randomised Controlled Trials of Traditional Chinese Medicine,” British Medical Journal, No. 319, No. 7203, 1999, pp. 160-161.
K. Linde, W. B. Jonas, D. Melchart and S. Willich, “The Methodological Quality of Randomized Controlled Trials of Homeopathy, Herbal Medicines and Acupuncture,” International Journal of Epidemiology, Vol. 30, No. 3, 2001, pp. 526-531. doi:10.1093/ije/30.3.526
L. Xu, J. Li, M. M. Zhang, C. L. Ai and L. Wang, “Chinese Authors Do Need CONSORT: Reporting Quality Assessment for Five Leading Chinese Medical Journals,” Contemporary Clinical Trials, Vol. 29, No. 5, 2008, pp. 727-731. doi:10.1016/j.cct.2008.05.003
I. D. Giovanna and G. Hayes, “Principles of Clinical Research,” Wrightson Biomedical Publishing Ltd., UK, 2001, p. 106.
L. Jian and C. Da-tong, “Evaluation of the Quality of Life in the Treatment of Malignant Tumor,” Chinese Journal of Oncology, Vol. 24, No. 4, 2002, pp. 411-413.
H. Schipper, J. Clinch, A. McMurray, et al., “Measuring the Quality of Life of Cancer Patients: The Functional Living Index-Cancer—Development and Validation,” Journal of Clinical Oncology, Vol. 2, No. 5, 1984, pp. 472-483.
T. Z. Zhang and G. W. Xu, “Oncology,” Tianjin Science and Technology Press, Tianjin, 1996, p. 830.
 M. Dharma-Wardene, H.-J. Au, J. Hanson, D. Dupere, J. Hewitt and D. Feeny, “Baseline FACT-G Score is a Predictor of Survival for Advanced Lung Cancer,” Quality of Life Research, Vol. 13, No. 7, 2004, pp. 1209-1216. doi:10.1023/B:QURE.0000037481.36604.eb
K. Gondek, P. P. Sagnier, K. Gilchrist and J. M. Woolley, “Current Status of Patient-Report Outcomes in Industry-Sponsored Oncology Clinical Trials and Product Labels,” Journal of Clinical Oncology, Vol. 25, No. 32, 2007, pp. 5087-5093. doi:10.1200/JCO.2007.11.3845
J. L. Tang, S. Y. Zhan and E. Ernst, “Review of Randomised Controlled Trials of Traditional Chinese Medicine,” British Medical Journal, Vol. 319, No. 7203, 1999, pp. 160-161.
P.-Ch. Leung, “A Practical Way of Research in Chinese Medicine,” Annals of the Academy of Medicine of Singapore, Vol. 35, No. 11, 2006, pp. 770-772.
M. Cavaille, “Coll Impact of Compliance on Drug Development: An FDA Perspective,” Transplantation Proceedings, Vol. 31, 1999, pp. 40S-41S.